The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review
<p dir="ltr">Intermittent fasting (IF) has recently gained popularity due to its emerging benefits in reducing weight and improving metabolic health. Concurrently, novel agents (NAs) like venetoclax and Bruton tyrosine kinase inhibitors (BTKIs) have revolutionized the treatment of ch...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513556003684352 |
|---|---|
| author | Maria Benkhadra (19756941) |
| author2 | Nuha Fituri (19756944) Soha Aboukhalaf (19756947) Rola Ghasoub (16555851) Mervat Mattar (17430972) Khalil Alfarsi (17430975) Salem Alshemmari (19756950) Mohamed A. Yassin (8361183) |
| author2_role | author author author author author author author |
| author_facet | Maria Benkhadra (19756941) Nuha Fituri (19756944) Soha Aboukhalaf (19756947) Rola Ghasoub (16555851) Mervat Mattar (17430972) Khalil Alfarsi (17430975) Salem Alshemmari (19756950) Mohamed A. Yassin (8361183) |
| author_role | author |
| dc.creator.none.fl_str_mv | Maria Benkhadra (19756941) Nuha Fituri (19756944) Soha Aboukhalaf (19756947) Rola Ghasoub (16555851) Mervat Mattar (17430972) Khalil Alfarsi (17430975) Salem Alshemmari (19756950) Mohamed A. Yassin (8361183) |
| dc.date.none.fl_str_mv | 2024-05-30T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/cancers16112079 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_Safety_of_Novel_Therapies_in_Chronic_Lymphocytic_Leukemia_in_the_Era_of_Intermittent_Fasting_A_Pharmacology-Based_Review/27130050 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Oncology and carcinogenesis chronic lymphocytic leukemia tumor lysis syndrome gastrointestinal bleeding intermittent fasting fluid-restricted intermittent fasting fluid-liberal intermittent fasting Bruton tyrosine kinase inhibitors (BTK) BCL2 inhibitors |
| dc.title.none.fl_str_mv | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Intermittent fasting (IF) has recently gained popularity due to its emerging benefits in reducing weight and improving metabolic health. Concurrently, novel agents (NAs) like venetoclax and Bruton tyrosine kinase inhibitors (BTKIs) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Unfortunately, it is unclear whether the associated risks of tumor lysis syndrome (TLS) and gastrointestinal bleeding (GIB) are increased in IF practitioners receiving NAs. This review explored the literature available on the permissibility of IF in CLL patients undergoing treatment with first-line NAs (FLNAs). Literature was scoped to identify IF patterns and the available data on TLS and GIB risks associated with food and fluid intake in CLL patients receiving FLNAs. Although current evidence is insufficient to recommend IF in this population, it may be possible for patients on venetoclax to conservatively practice fluid-liberal IF, provided that adequate hydration and the consistent administration of food are achieved. In contrast, considering the significant risk of TLS and the pharmacokinetics of venetoclax, patients should be discouraged from practicing fluid-restricted IF, especially during the ramp-up phase. Moreover, patients on BTKIs ought to refrain from IF due to the possible risk of GIB until further data are available. Further research is needed to provide conclusive recommendations.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancers<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cancers16112079" target="_blank">https://dx.doi.org/10.3390/cancers16112079</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_caec9bf0fc0e61df24e3cfdb3dfc1da3 |
| identifier_str_mv | 10.3390/cancers16112079 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/27130050 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based ReviewMaria Benkhadra (19756941)Nuha Fituri (19756944)Soha Aboukhalaf (19756947)Rola Ghasoub (16555851)Mervat Mattar (17430972)Khalil Alfarsi (17430975)Salem Alshemmari (19756950)Mohamed A. Yassin (8361183)Biomedical and clinical sciencesOncology and carcinogenesischronic lymphocytic leukemiatumor lysis syndromegastrointestinal bleedingintermittent fastingfluid-restricted intermittent fastingfluid-liberal intermittent fastingBruton tyrosine kinase inhibitors (BTK)BCL2 inhibitors<p dir="ltr">Intermittent fasting (IF) has recently gained popularity due to its emerging benefits in reducing weight and improving metabolic health. Concurrently, novel agents (NAs) like venetoclax and Bruton tyrosine kinase inhibitors (BTKIs) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Unfortunately, it is unclear whether the associated risks of tumor lysis syndrome (TLS) and gastrointestinal bleeding (GIB) are increased in IF practitioners receiving NAs. This review explored the literature available on the permissibility of IF in CLL patients undergoing treatment with first-line NAs (FLNAs). Literature was scoped to identify IF patterns and the available data on TLS and GIB risks associated with food and fluid intake in CLL patients receiving FLNAs. Although current evidence is insufficient to recommend IF in this population, it may be possible for patients on venetoclax to conservatively practice fluid-liberal IF, provided that adequate hydration and the consistent administration of food are achieved. In contrast, considering the significant risk of TLS and the pharmacokinetics of venetoclax, patients should be discouraged from practicing fluid-restricted IF, especially during the ramp-up phase. Moreover, patients on BTKIs ought to refrain from IF due to the possible risk of GIB until further data are available. Further research is needed to provide conclusive recommendations.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancers<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cancers16112079" target="_blank">https://dx.doi.org/10.3390/cancers16112079</a></p>2024-05-30T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/cancers16112079https://figshare.com/articles/journal_contribution/The_Safety_of_Novel_Therapies_in_Chronic_Lymphocytic_Leukemia_in_the_Era_of_Intermittent_Fasting_A_Pharmacology-Based_Review/27130050CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/271300502024-05-30T03:00:00Z |
| spellingShingle | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review Maria Benkhadra (19756941) Biomedical and clinical sciences Oncology and carcinogenesis chronic lymphocytic leukemia tumor lysis syndrome gastrointestinal bleeding intermittent fasting fluid-restricted intermittent fasting fluid-liberal intermittent fasting Bruton tyrosine kinase inhibitors (BTK) BCL2 inhibitors |
| status_str | publishedVersion |
| title | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review |
| title_full | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review |
| title_fullStr | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review |
| title_full_unstemmed | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review |
| title_short | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review |
| title_sort | The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review |
| topic | Biomedical and clinical sciences Oncology and carcinogenesis chronic lymphocytic leukemia tumor lysis syndrome gastrointestinal bleeding intermittent fasting fluid-restricted intermittent fasting fluid-liberal intermittent fasting Bruton tyrosine kinase inhibitors (BTK) BCL2 inhibitors |